Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 perioperative pembrolizumab plus chemotherapy versus placebo plus chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma
CTR20200983Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200983.